Top Stock Reports for T-Mobile, NextEra Energy and Amgen – September 8, 2022
Thursday, September 8, 2022
Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), NextEra Energy, Inc. (NEE) and Amgen Inc. (AMGN). These research reports have been handpicked from the approximately 70 reports published today by our team of analysts.
You can see all research reports from today here >>>
T-Mobile shares have outperformed industry Zacks Wireless National over the past year (+8.8% vs -11.5%). The company announced strong results in the second quarter of 2022 with healthy customer growth thanks to the diligent execution of operational plans. He raised the forecasts for 2022 in all areas. It is on track to complete the dismantling of the Sprint customer network by the end of the year.
The company has increased its 5G footprint in the country by introducing 5G home internet services in several states. Its extended 5G range covers 320 million people. Ultra Capacity 5G covers 235 million people.
However, it operates in a fiercely competitive and nearly saturated US telecommunications market, which somewhat reduces its growth potential. Several promotional activities aimed at attracting additional customers further erode the company’s profitability. In addition, the costs incurred to win customers and increase revenue have not yet been rewarded for shareholders.
(You can read the full T-Mobile research report here >>>)
NextEra Energy shares have gained +7.0% over the past year against the industry’s +11.9% gain Zacks Utility – Electric Power. The company, thanks to the good execution of organic projects and strategic acquisitions, is expanding its activities. NextEra Energy currently has a lot of renewable projects in its backlog and the backlog of renewable projects is growing every quarter, which helps the company reduce emissions.
The merger of Gulf Power and FPL strengthens NextEra Energy’s position in Florida. Florida’s improving economy and FPL’s reliable services are increasing its customer volume every quarter. NextEra Energy has sufficient liquidity to meet its short-term debt obligations.
However, the nature of its business is subject to complex federal, state and other regulations. Unfavorable weather conditions and an increase in supply costs have a negative impact on the results.
(You can read the full research report on NextEra Energy here >>>)
Amgen shares have outperformed industry Zacks Medical – Biomedical and Genetics over the past year (+17.2% vs -40.1%). The company’s leading drugs, such as Prolia, Repatha and Xgeva, are driving sales. Amgen is rapidly advancing its strong portfolio of early-stage and late-stage assets. The new drugs Lumakras and Tezspire are off to an encouraging start.
Label expansion studies on Lumakras are progressing rapidly. The acquisition of ChemoCentryx, if successfully completed, will add a new strategic growth asset in Tavneos to Amgen’s portfolio. Amgen has a strong biosimilar pipeline with potential new products that should drive long-term growth.
However, rising prices and competitive pressure are hurting sales of many Amgen products, including some biosimilars. Additionally, growing competition for its legacy products is hurting sales. The IRS tax dispute is an overhang on Amgen shares.
(You can read the full research report on Amgen here >>>)
Other noteworthy reports we feature today include Canadian National Railway Company (CNI), 3M Co. (MMM) and Itaú Unibanco Holding SA (ITUB).
Note: Sheraz Mian leads the equity research department at Zacks and is a well-known expert on overall earnings. He is frequently quoted in the written and electronic press and publishes the weekly Earnings Trends and Revenue overview reports. If you would like to receive an email notification whenever Sheraz publishes a new article, please click here>>>